Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In 5 clinical studies of Dry Eye Disease with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. 170 patients were exposed to Xiidra for approximately 12 months.1
Across 5 clinical studies, the most common adverse reactions (5-25%) were instillation site irritation, dysgeusia, and reduced visual acuity1
In the 12-month, multicenter, randomized, double-masked, phase 3 study, the safety of Xiidra compared to vehicle was evaluated in a total of 331 adults with Dry Eye Disease.1,2
CLICK TO ENLARGE
Incidence and severity of most frequent adverse events (>5%) in a 12-month safety study2*
The majority of ocular adverse reactions were considered mild to moderate in the 12-month study.2
Percentage value indicates the proportion of participants who experienced each type of adverse event.
Values inside bars = number of participants
*Adverse events occurring in >5% of participants in either treatment group.